Industry News
Pharmaceutical Industry News
CMI Media Group has stepped up its…
CMI Media Group has stepped up its play for the orphan drug marketing sector, unveiling a framework tailored to the promotion of complex, low-incidence therapies.
After investors blanched last…
After investors blanched last month at a slower-than-expected launch timeline for Celcuity’s novel breast cancer med Revtorpyk, the company used much of its latest earnings call to address concerns over—and reaffirm confidence in—the pace of
Is Motion Sickness Preventable?
Experts say there are ways to stave off that dreaded queasy feeling.
Canada-based Eurofins CDMO Alphora…
Canada-based Eurofins CDMO Alphora boosted its development and production to meet growing demand for both non-potent and high-potency APIs.
The phase 3 misstep could undercut…
The phase 3 misstep could undercut EyePoint’s ambition to displace Eylea as the high-value treatment of choice for wAMD, a leading cause of blindness in adults over 50, while putting significant pressure on the identical
Quanovate voluntarily agreed to…
Quanovate voluntarily agreed to discontinue the marketing claims on its Mira fertility monitor and test wands that competitor Procter & Gamble had challenged before the BBB National Programs’ National Advertising Division.
In the first major workforce…
In the first major workforce reduction disclosed under new CEO Belén Garijo, Sanofi is laying off 229 employees from legacy Blueprint Medicines in Massachusetts as part of a post-acquisition integration.
Sandoz has collaborated with…
Sandoz has collaborated with Shanghai Henlius to gain commercialization rights to three biosimilars that are in early development. The deal is for Sandoz to pay up to $100.5 million up front for the initial assets
With its latest trial readout for…
With its latest trial readout for under-the-skin efgartigimod, argenx is adding another feather to the FcRn blocker’s cap.
AstraZeneca reported phase 3 lung…
AstraZeneca reported phase 3 lung cancer wins for Enhertu and a combination of Orpathys and Tagrisso, but the victories were eclipsed by the failure of its PD-1/CTLA-4 bispecific antibody in a simultaneous readout.
How One Woman With a Very Rare Disease Secured a Clinical Trial
Through sheer determination, Neena Nizar has become the first patient in a clinical trial testing a treatment for her disease — one so rare it affects just 30 people worldwide.
The pharmaceutical industry…
The pharmaceutical industry creates some of the most valuable products in human history: Medicines that can extend, save and better our lives. The product is rarely up for question, but the industry itself can struggle
Politicians and health group…
Politicians and health group leaders in Denmark are calling out Eli Lilly’s obesity awareness campaign in the country.
A U.S. appeals court has revived a…
A U.S. appeals court has revived a lawsuit filed by Celgene shareholders that accuses Bristol Myers Squibb of slow-playing the approval of blood cancer drug Breyanzi to avoid paying out a more than $6 billion
With the European Union formally…
With the European Union formally reversing its marketing authorization for the rare-disease med Tavneos last week, regulators in the bloc are laying out their concerns about the data backing the complement inhibitor in greater detail.
In a historic breakthrough for…
In a historic breakthrough for targeted protein degradation, BMS has secured the first FDA approval for a CELMoD therapy with the clearance of Zenbexus (iberdomide), marking the first multiple myeloma approval driven directly by minimal
As Legend Biotech became…
As Legend Biotech became profitable, the company is navigating Carvykti's next phase of growth. Taiho and Cullinan's EGFR candidate delivered a phase 3 win. WuXi AppTec won a preliminary injunction against the Defense Department's black
With its reserves depleted, a debt…
With its reserves depleted, a debt payment due in four weeks and its cash runway stretching only into next month, the question for Karyopharm Therapeutics is what’s next and how soon can it happen? The
As the massive market for GLP-1…
As the massive market for GLP-1 weight-loss drugs continues to come into its own, patients are just now discovering their preferences, and the appetite for differentiation will likely increase as more drugs are approved in
AstraZeneca’s newly approved…
AstraZeneca’s newly approved blood pressure drug Baxfendy does not clear the bar for effectiveness relative to its price, according to U.S. drug price watchdog ICER.